Cancer Diagnostics – Multimedia

Minimal carry-over is a prerequisite for high throughput analysis. However, minimized carry-over and cycle time are competing and a careful optimization is mandatory. In this study the influence of wash conditions on carry-over of various compounds was investigated. A strategy to minimize carry-over was developed. The influences of different wash tasks were investigated. Finally the contribution of different system components such as injector valve or column was studied.

SDS-PAGE separates protein samples from LC-MS incompatible contaminations, and is frequently used to fractionate proteins of entire proteomes. One disadvantage is that gel lanes have to be cut into many slices, followed by in-gel digestion of proteins and extraction of peptides. The number of these gel slices goes into the hundreds, rendering this process very repetitive and prone to mistakes and errors during sample handling. Automation reduces such risks and improves reproducibility.

Marketa Bockova, Institute of Photonics and Electronics ASCR, speaking at Biodetection & Biosensors 2015

This presentation will outline key issues in oncology biomarker testing and describe findings from a study of practices used by National Cancer Institute (NCI) designated cancer centers, the leading U.S. oncology institutions, for testing key biomarkers in three solid tumors - breast, gastroesophageal and non-small cell lung cancers.

Seth Crosby, Washington University School of Medicine, discusses both bench and informatic methods used to increase specificity in the apprehension of rare cfDNA alleles.

Jeff Cummings presents a worked example of circulating tumour cell enumeration as a prognostic/predictive biomarker in cancer research.

Paramagnetic Dynabeads® magnetic beads provide a versatile, automation friendly tool for fast sensitive and high throughput isolation that can be tailored to isolate specific circulating biomarkers such as cells, exosomes and nucleic acids.

In patients with NSCLC, Electric Field–Induced Release and Measurement (EFIRM) can detect EGFR mutations directly in saliva. This enables clinicians to adjust their therapeutic strategies in a timely fashion, consequently improving the clinical outcome of EGFR-targeted therapy.

A novel amplicon approach allowing for hundreds of amplicons to be multiplexed in a single tube with a two workflow from sample to sequencer.

We show non-responders to treatment among breast cancer patients can be identified by expression profiling of circulating tumor cells